Among the eight participants with confirmed BRCA1/2 P/LP variants, four males (participants #1, 2, 3, and #8) were offered surveillance that included breast examination and imaging, as well as follow-ups for prostate cancer at the urology–oncology department, which involved blood tests and clinical assessments. This evidence concerns the gene BRCA1 and prostate carcinoma.